Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03666273
Recruitment Status : Recruiting
First Posted : September 11, 2018
Last Update Posted : March 29, 2021
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Bayer

Tracking Information
First Submitted Date  ICMJE September 10, 2018
First Posted Date  ICMJE September 11, 2018
Last Update Posted Date March 29, 2021
Actual Study Start Date  ICMJE September 12, 2018
Estimated Primary Completion Date November 30, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 19, 2019)
  • Incidence of treatment-emergent AEs (TEAEs) including treatment-emergent serious adverse events (TESAEs), adverse events of special interest (AESIs), and dose-limiting toxicities (DLTs) [ Time Frame: Up to 58 months ]
  • Severity of treatment-emergent AEs (TEAEs) including treatment-emergent serious adverse events (TESAEs), adverse events of special interest (AESIs), and dose-limiting toxicities (DLTs) [ Time Frame: Up to 58 months ]
  • Cmax of BAY1905254 after first dose administration (Cycle 1) for cohorts receiving doses ≥ 20 mg [ Time Frame: Up to 504 hours after drug in Cycle 1 ]
    Maximum plasma concentration after single dose
  • AUC of BAY1905254 after first dose administration (Cycle 1) for cohorts receiving doses ≥ 20 mg [ Time Frame: Up to 504 hours after drug in Cycle 1 ]
    Area under the plasma concentration curve after single dose
  • Maximum tolerated dose (MTD) of BAY1905254 [ Time Frame: Up to 58 months ]
Original Primary Outcome Measures  ICMJE
 (submitted: September 10, 2018)
  • The incidence of treatment-emergent AEs (TEAEs) including treatment-emergent serious adverse events (TESAEs) and adverse events of special interest (AESIs), and dose-limiting toxicities (DLTs) [ Time Frame: Up to 2 years ]
  • The severity of treatment-emergent AEs (TEAEs) including treatment-emergent serious adverse events (TESAEs) and adverse events of special interest (AESIs), and dose-limiting toxicities (DLTs) [ Time Frame: Up to 2 years ]
  • Cmax of BAY1905254 after first dose administration (Cycle 1) for cohorts receiving doses ≥ 20 mg [ Time Frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 24, 48, 96, 168, 264, 336 and (504) hours after drug in Cycle 1 ]
    Maximum plasma concentration after single dose
  • AUC (of the respective dosing interval) of BAY1905254 after first dose administration (Cycle 1) for cohorts receiving doses ≥ 20 mg [ Time Frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 24, 48, 96, 168, 264, 336 and (504) hours after drug in Cycle 1 ]
    Area under the plasma concentration curve from 0 to 336 hours after single dose (Q2W(every 2 weeks) only); Area under the plasma concentration curve from 0 to 504 hours after single dose (Q3W (every 3 weeks) only)
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 25, 2019)
  • Recommended dose of BAY1905254 for Phase 2 [ Time Frame: Up to 58 months ]
  • Cmax,md after multiple dosing (Cycle 3) for cohorts receiving doses ≥ 20 mg [ Time Frame: Up to 504 hours after drug in Cycle 3 ]
    Maximum plasma concentration after multiple doses
  • AUC after multiple dosing (Cycle 3) for cohorts receiving doses ≥ 20 mg [ Time Frame: Up to 504 hours after drug in Cycle 3 ]
    Area under the plasma concentration curve after multiple doses
  • Incidence of positive anti-drug antibody and neutralizing antibody titer for BAY1905254 [ Time Frame: Up to 58 months ]
  • Best overall response rate [ Time Frame: Up to 58 months ]
    Determined by RECIST 1.1
Original Secondary Outcome Measures  ICMJE
 (submitted: September 10, 2018)
  • Cmax,md of the respective dosing interval after multiple dosing in Cycle 3 Day 1 for cohorts receiving doses ≥ 20 mg [ Time Frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 24, 48, 96, 168, 264, 336 and (504) hours after drug in Cycle 3 ]
    Maximum plasma concentration after multiple doses
  • AUC of the respective dosing interval after multiple dosing in Cycle 3 Day 1 for cohorts receiving doses ≥ 20 mg [ Time Frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 4, 6, 24, 48, 96, 168, 264, 336 and (504) hours after drug in Cycle 3 ]
    Area under the plasma concentration curve from 0 to 336 hours after multiple doses (Q2W only); Area under the plasma concentration curve from 0 to 504 hours after multiple doses (Q3W only)
  • Best overall response rate (BORR) [ Time Frame: Up to 2 years ]
  • Incidence of positive anti-drug antibody and neutralizing antibody titer [ Time Frame: Up to 2 years ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254
Official Title  ICMJE An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics and Tumor Response Profile of the ILDR2 Function-blocking Antibody BAY1905254 in Patients With Advanced Solid Tumors
Brief Summary The main purpose of this clinical study is to determine the most appropriate dose of the study medication that can be safely given to cancer patients alone or in combination with another cancer drug, and to look at how the study medication is changed and distributed by the body.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Advanced Solid Tumor
Intervention  ICMJE
  • Drug: BAY1905254
    Intravenous administration of escalating doses of BAY1905254
  • Drug: BAY1905254 + Pembrolizumab
    Intravenous administration of BAY1905254 of fixed dose (expansion), and of a fixed dose of pembrolizumab
Study Arms  ICMJE
  • Experimental: Dose escalation_Monotherapy
    Patients with solid tumor types considered immunosensitive
    Intervention: Drug: BAY1905254
  • Experimental: Dose escalation_Combination therapy
    Patients with solid tumor types considered immunosensitive
    Intervention: Drug: BAY1905254 + Pembrolizumab
  • Experimental: Expansion HNSCC_Combination therapy
    Patients with head and neck squamous cell carcinoma (HNSCC)
    Intervention: Drug: BAY1905254 + Pembrolizumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: October 22, 2020)
120
Original Estimated Enrollment  ICMJE
 (submitted: September 10, 2018)
196
Estimated Study Completion Date  ICMJE May 30, 2024
Estimated Primary Completion Date November 30, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Main Inclusion Criteria:

  • Male or female patients aged ≥ 18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  • Patients must have measurable disease (at least one unidimensional measurable lesion by Computed tomography [CT] or Magnetic resonance imaging [MRI]) per Response evaluation criteria in solid tumors (RECIST) 1.1, and following histologically confirmed, advanced or metastatic solid tumors:

    • Dose escalation: All solid tumor types with a likelihood of sensitivity to immunotherapy, as judged by the investigator.
    • Expansion of BAY 1905254 in combination with pembrolizumab in Head and neck squamous cell carcinoma (HNSCC): recurrent or metastatic head and neck squamous cell carcinoma IO-naïve PDL1+/ CPS≥1(PD-L1: Programmed death ligand 1; CPS: Combined positive score).
  • Provision of archival tumor tissue at screening is mandatory for all patients in dose escalation.
  • For dose escalation, patients: must have received standard therapy or have no standard therapy available or patients have actively refused any treatment which would be regarded standard. Or in the opinion of investigator have been considered ineligible for a particular form of standard therapy on medical grounds.
  • Adequate bone marrow, liver and renal function.
  • Adequate cardiac function, measured by echocardiography.

Main Exclusion Criteria:

  • History of severe immune related adverse effects from prior immunotherapy (CTCAE v.5.0 Grade 4; CTCAE v.5.0 Grade 3 requiring treatment > 4 weeks), except hypothyroidism clinically stable on hormone replacement treatment and controlled type 1 diabetes.
  • Severe (CTCAE v.5.0 Grade ≥ 3) infections within 4 weeks before the first study drug administration, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia. Clinically active infections (CTCAE v.5.0 > Grade 1) within 2 weeks before the first study drug administration.
  • Previous or active myocarditis/myositis in history (independent of cause)
  • Active or history of autoimmune disease.
  • Known human immunodeficiency virus (HIV) infection.
  • Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
  • Treatment with systemic immunosuppressant medications within 2 weeks before the first study drug administration.
  • Ongoing or previous anti-cancer treatment or any immunostimulatory treatment including but not limited to interferons (IFNs), interleukin (IL)-2 and agonists for members of the tumor necrosis factor (TNF) receptor superfamily (e.g. 4-1BB) within 4 weeks before the first study drug administration.
  • For dose expansion cohort of BAY 1905254 in combination with pembrolizumab in HNSCC: has progressive disease (PD) within six (6) months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Bayer Clinical Trials Contact (+)1-888-8422937 clinical-trials-contact@bayer.com
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03666273
Other Study ID Numbers  ICMJE 18789
MK-3475-920 ( Other Identifier: Merck )
2018-000990-63 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Bayer
Study Sponsor  ICMJE Bayer
Collaborators  ICMJE Merck Sharp & Dohme Corp.
Investigators  ICMJE
Study Director: Bayer Study Director Bayer
PRS Account Bayer
Verification Date March 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP